Blacksburg, VA, United States of America

Sanjib Bera

This inventor holds 27 USPTO granted patents and 17 published patent applications, plus 8 CIPO patents and 5 EPO patents, primarily in Prodrug Chemistry. Top assignees: Kempharm, Inc., Zevra Therapeutics, Inc., Isis Pharmaceuticals, Inc.. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sanjib Bera. Retrieved from https://idiyas.com/inventor/sanjib-bera

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 17)

% Patents Active = 96.3

CIPO Patents = 8 (Patent Applications = 5)

EPO Patents = 5 (Patent Applications = 12)

Average Co-Inventor Count = 3.8

ph-index = 6

Forward Citations = 131(Granted Patents)

Location History:

Blackburg, VA (US) (2020)
Blacksburg, VA (US) (2007 - 2024)

Company Filing History:

Zevra Therapeutics, Inc.

patents

1 out of 1,035

Isis Pharmaceuticals, Inc.

New River Pharmaceuticals Inc.

where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

Prodrugs

Dextrorphan

Levorphanol

Quetiapine

Benzoic Acid

Amino Acid Conjugates

Fatty Acid Conjugates

Methylphenidate

Gamma-Hydroxybutyrate

Oxymorphone

Oxycodone

Nucleoside Compounds

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12662456 - Dextrorphan prodrugs and processes for making and using them (2026-06-23),

2. 12590065 - Levorphanol prodrugs and processes for making and using them (2026-03-31),

3. 12251445 - Gamma-hydroxybutyrate delivering compounds and processes for making and using them (2025-03-18),

4. 12076316 - Levorphanol prodrugs and processes for making and using them (2024-09-03),

5. 12012384 - Dextrorphan prodrugs and processes for making and using them (2024-06-18),

6. 11234975 - Levorphanol prodrugs and processes for making and using them (2022-02-01),

7. 11214544 - Dextrorphan prodrugs and processes for making and using them (2022-01-04),

8. 10758528 - Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof (2020-09-01),

9. 10544153 - Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone, prodrugs, methods of making and use thereof (2020-01-28),

10. 10463660 - Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof (2019-11-05),

11. 10231960 - Methylphenidate-prodrugs, processes of making and using the same (2019-03-19),

12. 10144740 - Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone, prodrugs, methods of making and use thereof (2018-12-04),

13. 10071091 - Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof (2018-09-11),

14. 10010615 - Amino acid conjugates of quetiapine, process for making and using the same (2018-07-03),

15. 9890150 - Fatty acid conjugates of quetiapine, process for making and using the same (2018-02-13),

Title: Innovations and Contributions of Sanjib Bera in Pharmaceutical Patents

Introduction

Sanjib Bera, based in Blacksburg, VA, is a prominent inventor recognized for his innovative contributions to the pharmaceutical industry. With a remarkable portfolio of 24 patents, he has significantly advanced the field with his pioneering work on prodrugs and therapeutic compositions.

Latest Patents

One of Sanjib Bera's notable patents is focused on "Levorphanol prodrugs and processes for making and using them." This technology encompasses compositions involving oxoacids, amino acids, polyethylene glycols, and vitamin compounds that are chemically conjugated to levorphanol, ((−)-17-methylmorphinan-3-ol). The invention seeks to develop novel prodrugs and enhance the therapeutic applications of levorphanol.

Another significant patent is on "Dextrorphan prodrugs and processes for making and using them." This invention similarly involves compositions that include oxoacids, polyethylene glycols, and vitamin compounds chemically bonded to dextrorphan, (+)-17-methylmorphinan-3-ol, aiming to create new prodrugs and compositions for dextrorphan.

Career Highlights

Sanjib Bera has made substantial contributions to pharmaceutical research through his work at various institutions. He has been associated with companies such as Kempharm Inc. and Zevra Therapeutics Inc., where he applied his expertise to developing advanced therapeutic solutions.

Collaborations

Throughout his career, Sanjib Bera has collaborated with several talented individuals, including Sven Guenther and Travis C Mickle. These collaborations have enriched his research and led to innovative approaches in developing new pharmaceutical compositions.

Conclusion

Sanjib Bera's extensive patent portfolio and collaborative efforts underscore his critical role in driving innovation in the pharmaceutical sector. His work on prodrugs significantly enhances the potential of drugs like levorphanol and dextrorphan, paving the way for improved therapeutic options. As the field of pharmaceuticals continues to evolve, his contributions will undoubtedly have a lasting impact on healthcare.

Profile summary based on public USPTO records.